COLTRO, GIACOMO
 Distribuzione geografica
Continente #
NA - Nord America 712
EU - Europa 481
AS - Asia 181
SA - Sud America 3
Totale 1.377
Nazione #
US - Stati Uniti d'America 705
IT - Italia 140
IE - Irlanda 121
HK - Hong Kong 85
SE - Svezia 73
CH - Svizzera 61
RU - Federazione Russa 57
CN - Cina 52
SG - Singapore 21
JO - Giordania 16
DE - Germania 11
CA - Canada 7
GB - Regno Unito 6
IN - India 4
BR - Brasile 3
FR - Francia 3
AT - Austria 2
ES - Italia 2
FI - Finlandia 2
JP - Giappone 2
UA - Ucraina 2
KR - Corea 1
PL - Polonia 1
Totale 1.377
Città #
Dublin 121
Ashburn 94
Fairfield 80
Chandler 68
Bern 61
Hong Kong 55
Moscow 51
Woodbridge 37
Cambridge 36
Seattle 34
Altamura 31
Lawrence 30
Houston 25
Kent 23
Wilmington 23
Buffalo 18
Florence 18
Princeton 18
Shanghai 18
Beijing 14
Boston 13
New York 12
Washington 12
Ann Arbor 11
Singapore 9
Sesto Fiorentino 8
Bremen 7
Milan 6
Pian di Scò 6
West Jordan 6
Boardman 5
Cervia 5
Fiesole 5
Medford 5
San Diego 5
Hillsboro 4
Napoli 4
Pune 4
Toronto 4
Hangzhou 3
San Jose 3
Andover 2
Cagliari 2
Chengdu 2
Cortona 2
Dearborn 2
Fuzhou 2
Hefei 2
Jacksonville 2
Los Angeles 2
Maranello 2
Norwalk 2
Paris 2
Pisa 2
Red Deer 2
Reston 2
Rimini 2
Rome 2
San Giovanni Valdarno 2
Sant'elpidio A Mare 2
Seville 2
Shenzhen 2
Siena 2
São Leopoldo 2
Tokyo 2
Vienna 2
Villa Minozzo 2
Abenberg 1
Azzano Decimo 1
Brescia 1
Brugherio 1
Caronno Pertusella 1
Catania 1
Catanzaro 1
Falkenstein 1
Falls Church 1
Fano 1
Fiumicino 1
Fontebuona 1
Hounslow 1
Kunming 1
Lappeenranta 1
Leawood 1
Livorno 1
London 1
Monteriggioni 1
Montreal 1
New Bedfont 1
Noisy-le-sec 1
Portland 1
Redwood City 1
Royal Oak 1
San Mateo 1
Saviano 1
Scarperia e San Piero 1
Seoul 1
Southwark 1
Specchia 1
São Paulo 1
Trumbull 1
Totale 1.077
Nome #
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study 97
A life-threatening ruxolitinib discontinuation syndrome 96
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative 88
Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) 81
Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients 76
Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients 75
Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature 72
Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Adult Patients 60
RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features 58
Integration of molecular information in risk assessment of patients with myeloproliferative neoplasms 43
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera 43
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis 40
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms 38
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis 36
Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities 34
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis 33
Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2V617F Variant Allele Frequency≤ 1% 29
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 28
Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment 28
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 27
Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients 27
Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of TET2 and ZRSR2 mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving CDK2NA/2NB and MTAP 27
Mutations and thrombosis in essential thrombocythemia 27
Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis 26
The safety of JAK kinase inhibitors for the treatment of myelofibrosis 26
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis 26
Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia 25
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis 19
Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms 18
Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis 18
Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis 16
Response to erythropoiesis‐stimulating agents in patients with WHO‐defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN‐RS‐T) 16
RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis 16
The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions 15
A challenging diagnosis of myeloid/lymphoid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement 14
Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients 13
Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms 11
Thrombotic risk correlates with mutational status in true essential thrombocythemia 10
Hematologic Neoplasms Associated with Down Syndrome: Cellular and Molecular Heterogeneity of the Diseases 8
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis 5
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates 4
Totale 1.449
Categoria #
all - tutte 8.649
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.649


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020143 4 1 2 10 11 16 23 26 21 10 11 8
2020/2021125 2 8 25 38 4 6 3 10 9 8 9 3
2021/2022110 2 1 3 1 4 5 0 22 14 1 23 34
2022/2023559 34 87 36 23 56 90 69 21 35 15 16 77
2023/2024445 18 25 56 18 39 75 11 79 12 50 43 19
2024/202533 33 0 0 0 0 0 0 0 0 0 0 0
Totale 1.449